Volume 4, Issue 7

Understanding AE in the New ART Regimens

In this issue:

Antiretroviral therapy is continually improving, as new agents and combinations of agents become available that decrease the severe morbidity and mortality associated with HIV infection. As patients’ lifespans increase, it becomes more and more important for clinicians to consider the potential short-term and especially the potential long-term adverse effects of the medications they prescribe.

In this issue, Dr. Cody Chastain from the Division of Infectious Diseases at Vanderbilt University Medical Center reviews the recent postmarketing surveillance that goes beyond the clinical trials to identify previously unrecognized adverse events associated with some of the newer HIV medications.

Learning objectives:

  • Discuss the current evidence associating an increased rate of neural tube defects with using dolutegravir in pregnancy.
  • Compare the association of darunavir’s cardiovascular events profile with the emerging benefits/possible risks of dolutegravir’s lipid-lowering and weight-gain effects.
  • Describe the frequency and severity of neuropsychiatric adverse effects related to integrase strand transfer inhibitors (INSTI), including dolutegravir.

Author:

Cody Chastain, M.D.
Cody Chastain, M.D.

Assistant Professor of Medicine
Division of Infectious Diseases
Vanderbilt University Medical Center 
Nashville, TN 

Program Directors:

Allison L. Agwu, MD, ScM, FAAP, FIDSA

Associate Professor of Pediatrics and Adult Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Alysse G. Wurcel, MD, MS

Assistant Professor
Division of Geographic Medicine and Infectious Diseases
Tufts Medical Center
Boston, Massachusetts

Justin Alves, RN, ACRN, CARN
Infectious Disease Associates
Massachusetts General Hospital
Boston, Massachusetts

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: February 28, 2019
Expiration date: February 27, 2021